A Marathon Not a Sprint: Improving Outcomes for Patients With Metastatic Melanoma in 2022 and Beyond This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the ...
Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
A recent study reveals significant progress in biomarker testing for lung cancer in community settings, highlighting the need ...
NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...
The U.S. Food and Drug Administration (FDA) has approved Guardant360 CDx as a companion diagnostic to identify patients with ...
Dec 15 (Reuters) - Biocartis Group Nv : * Biocartis Group: CE-marking Idylla NRAS-BRAF mutation test completes offering of metastatic colorectal cancer tests for clinical use on Idylla platform Source ...
Deep-learning analysis of routine H&E slides accurately predicts key NSCLC driver mutations, supporting treatment in lung cancer care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results